MX2023001881A - Tratamiento con ribitol. - Google Patents

Tratamiento con ribitol.

Info

Publication number
MX2023001881A
MX2023001881A MX2023001881A MX2023001881A MX2023001881A MX 2023001881 A MX2023001881 A MX 2023001881A MX 2023001881 A MX2023001881 A MX 2023001881A MX 2023001881 A MX2023001881 A MX 2023001881A MX 2023001881 A MX2023001881 A MX 2023001881A
Authority
MX
Mexico
Prior art keywords
ribitol
treatment
disorder
disease
treating
Prior art date
Application number
MX2023001881A
Other languages
English (en)
Spanish (es)
Inventor
Qi Long Lu
Bo Wu
Original Assignee
The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health filed Critical The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health
Publication of MX2023001881A publication Critical patent/MX2023001881A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Molecular Biology (AREA)
MX2023001881A 2020-09-10 2021-09-09 Tratamiento con ribitol. MX2023001881A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063076761P 2020-09-10 2020-09-10
PCT/US2021/049677 WO2022056137A1 (en) 2020-09-10 2021-09-09 Ribitol treatment

Publications (1)

Publication Number Publication Date
MX2023001881A true MX2023001881A (es) 2023-04-03

Family

ID=80629815

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001881A MX2023001881A (es) 2020-09-10 2021-09-09 Tratamiento con ribitol.

Country Status (10)

Country Link
US (1) US20230364118A1 (https=)
EP (1) EP4210708A4 (https=)
JP (1) JP2023544249A (https=)
KR (1) KR20230069941A (https=)
CN (1) CN117355310A (https=)
AU (1) AU2021338706A1 (https=)
CA (1) CA3191582A1 (https=)
IL (1) IL301088A (https=)
MX (1) MX2023001881A (https=)
WO (1) WO2022056137A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10434113B2 (en) 2016-12-16 2019-10-08 The Charlotte Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
AU2020283556A1 (en) 2019-05-28 2022-01-06 The Charlotte-Mecklenburg Hospital Authority D/B/A Atrium Health Compositions and methods of making ribitol

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245235B2 (en) * 2016-12-16 2019-04-02 The Charlotte-Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
US20200061092A1 (en) * 2018-08-24 2020-02-27 The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health Methods and compositions for treating disorders associated with muscle weakness

Also Published As

Publication number Publication date
CA3191582A1 (en) 2022-03-17
AU2021338706A1 (en) 2023-05-25
CN117355310A (zh) 2024-01-05
EP4210708A1 (en) 2023-07-19
EP4210708A4 (en) 2024-10-23
WO2022056137A1 (en) 2022-03-17
IL301088A (en) 2023-05-01
JP2023544249A (ja) 2023-10-23
US20230364118A1 (en) 2023-11-16
KR20230069941A (ko) 2023-05-19
WO2022056137A9 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
PH12020551427A1 (en) Epinephrine spray formulations
BR112022007677A2 (pt) L-asparaginase recombinante
MX2022011550A (es) Composiciones y métodos para inhibir la expresión de angptl3.
PH12021552763A1 (en) Treatment and prevention of metabolic diseases
EA202092154A1 (ru) Комбинированная терапия
WO2023009834A3 (en) Methods of treating cancer
MX2023006146A (es) Composiciones bacterianas diseñadas para tratar la enfermedad de injerto contra huésped.
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2023001881A (es) Tratamiento con ribitol.
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
EP1556068A4 (en) TREATMENT OF AUTISM AND SIMULTANEOUS DISEASES
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
CR20230121A (es) Tratamiento de la enfermedad de parkinson
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MA56386B1 (fr) Polythérapie comprenant de l'acétyl-leucine et du miglustat pour le traitement d'une maladie lysosomale
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
AU2020327022A8 (en) Method of treating cancer
MX2021013351A (es) Terapias de combinacion.
WO2021226442A3 (en) Therapeutic uses of c3-binding agents
BR112022010042A2 (pt) Composições de hialuronidase e métodos de uso da mesma para tratar celulite
MX2021015292A (es) Interacciones terapeuticas de leucometiltioninio.
EP4706653A3 (en) Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers
MX2024005084A (es) Tratamientos administrados de manera subcutanea para enfermedad de parkinson avanzada.
WO2019232203A3 (en) Methods and compositions to alleviate vascular permeability